UPDATE 1-Merck steals march on rivals in lung cancer drug combo race

UPDATE 1-Merck steals march on rivals in lung cancer drug combo race


Merck & Co has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer, potentially giving it a major lift in the battle for the largest cancer market. U.S. regulators have agreed to a speedy review of Merck's application to combine its immune system-boosting drug Keytruda with chemotherapy as an initial therapy for advanced lung cancer, the U.S. drugmaker said.



from Biotech News